cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.6620360.v1
title: Supplementary Material for: Retinal Endovascular Surgery with Tissue Plasminogen Activator Injection for Central Retinal Artery Occlusion

description: <b><i>Purpose:</i></b> To report 2 cases of central retinal artery occlusion (CRAO) who underwent retinal endovascular surgery with injection of tissue plasminogen activator (tPA) into the retinal artery and showed a remarkable improvement in visual acuity and retinal circulation. <b><i>Methods:</i></b> Standard 25-G vitrectomy was performed under local anesthesia. Simultaneously, tPA (80,000 units/mL) solution was injected into the retinal artery of the optic disc for 2–3 min using a microneedle. Changes in visual acuity, fundus photography, optical coherence tomography (OCT), fluorescein angiography, and laser speckle flowgraphy (LSFG) results were examined. <b><i>Results:</i></b> Both cases could be treated within 12 h after the onset of CRAO. Case 1 was a 47-year-old woman. Her visual acuity improved from counting fingers before operation to 0.08 logMAR 1 month after the surgery. However, thinning of the retina at the macula was observed by OCT. Case 2 was a 70-year-old man. His visual acuity improved from counting fingers to 0.1 logMAR 2 months after the surgery. Both fluorescein angiography and LSFG showed improvement in retinal circulation after the surgery in case 2. <b><i>Conclusions:</i></b> Retinal endovascular surgery with injection of tPA into the retinal artery was feasible and may be a way to improve visual acuity and retinal circulation when performed in the acute phase of CRAO.
DOI: 10.6084/m9.figshare.6620348
title: Supplementary Material for: Clinical and Imaging Predictors of Recurrent Ischemic Stroke: A Systematic Review and Meta-Analysis

description: <b><i>Background:</i></b> Predictors of recurrent ischemic stroke are less well known in patients with a recent ischemic stroke than in patients with transient ischemic attack (TIA). We identified clinical and radiological factors for predicting recurrent ischemic stroke in patients with recent ischemic stroke. <b><i>Methods:</i></b> A systematic search in PubMed, Embase, Cochrane Library, and CINAHL was performed with the terms “ischemic stroke,” “predictors/determinants,” and “recurrence.” Quality assessment of the articles was performed and the level of evidence was graded for the articles included for the meta-analysis. Pooled risk ratios (RR) and heterogeneity (<i>I</i><sup>2</sup>) were calculated using inverse variance random effects models. <b><i>Results:</i></b> Ten articles with high-quality results were identified for meta-analysis. Past medical history of stroke or TIA was a predictor of recurrent ischemic stroke (pooled RR 2.5, 95% CI 2.1–3.1). Small vessel strokes were associated with a lower risk of recurrence than large vessel strokes (pooled RR 0.3, 95% CI 0.1–0.7). Patients with stroke of an undetermined cause had a lower risk of recurrence than patients with large artery atherosclerosis (pooled RR 0.5, 95% CI 0.2–1.1). We found no studies using CT or ultrasound for the prediction of recurrent ischemic stroke. The following MRI findings were predictors of recurrent ischemic stroke: multiple lesions (pooled RR 1.7, 95% CI 1.5–2.0), multiple stage lesions (pooled RR 4.1, 95% CI 3.1–5.5), multiple territory lesions (pooled RR 2.9, 95% CI 2.0–4.2), chronic infarcts (pooled RR 1.5, 95% CI 1.2–1.9), and isolated cortical lesions (pooled RR 2.2, 95% CI 1.5–3.2). <b><i>Conclusions:</i></b> In patients with a recent ischemic stroke, a history of stroke or TIA and the subtype large artery atherosclerosis are associated with an increased risk of recurrent ischemic stroke. Predictors evaluated with MRI include multiple ischemic changes and isolated cortical lesions. Predictors of recurrent ischemic stroke concerning CT or ultrasound have not been published.
DOI: 10.6084/m9.figshare.6620348.v1
title: Supplementary Material for: Clinical and Imaging Predictors of Recurrent Ischemic Stroke: A Systematic Review and Meta-Analysis

description: <b><i>Background:</i></b> Predictors of recurrent ischemic stroke are less well known in patients with a recent ischemic stroke than in patients with transient ischemic attack (TIA). We identified clinical and radiological factors for predicting recurrent ischemic stroke in patients with recent ischemic stroke. <b><i>Methods:</i></b> A systematic search in PubMed, Embase, Cochrane Library, and CINAHL was performed with the terms “ischemic stroke,” “predictors/determinants,” and “recurrence.” Quality assessment of the articles was performed and the level of evidence was graded for the articles included for the meta-analysis. Pooled risk ratios (RR) and heterogeneity (<i>I</i><sup>2</sup>) were calculated using inverse variance random effects models. <b><i>Results:</i></b> Ten articles with high-quality results were identified for meta-analysis. Past medical history of stroke or TIA was a predictor of recurrent ischemic stroke (pooled RR 2.5, 95% CI 2.1–3.1). Small vessel strokes were associated with a lower risk of recurrence than large vessel strokes (pooled RR 0.3, 95% CI 0.1–0.7). Patients with stroke of an undetermined cause had a lower risk of recurrence than patients with large artery atherosclerosis (pooled RR 0.5, 95% CI 0.2–1.1). We found no studies using CT or ultrasound for the prediction of recurrent ischemic stroke. The following MRI findings were predictors of recurrent ischemic stroke: multiple lesions (pooled RR 1.7, 95% CI 1.5–2.0), multiple stage lesions (pooled RR 4.1, 95% CI 3.1–5.5), multiple territory lesions (pooled RR 2.9, 95% CI 2.0–4.2), chronic infarcts (pooled RR 1.5, 95% CI 1.2–1.9), and isolated cortical lesions (pooled RR 2.2, 95% CI 1.5–3.2). <b><i>Conclusions:</i></b> In patients with a recent ischemic stroke, a history of stroke or TIA and the subtype large artery atherosclerosis are associated with an increased risk of recurrent ischemic stroke. Predictors evaluated with MRI include multiple ischemic changes and isolated cortical lesions. Predictors of recurrent ischemic stroke concerning CT or ultrasound have not been published.
DOI: 10.6084/m9.figshare.6619931
title: Supplementary Material for: Once-Weekly Administration of Sustained-Release Growth Hormone in Korean Prepubertal Children with Idiopathic Short Stature: A Randomized, Controlled Phase II Study

description: <b><i>Background/Aims:</i></b> To determine the optimal dose of LB03002, a sustained-release, once-weekly formulation of recombinant human growth hormone (rhGH), and to compare its efficacy and safety with daily rhGH in children with idiopathic short stature (ISS). <b><i>Methods:</i></b> This multicenter, randomized, open-label, phase II study included<b><i></i></b> GH-naïve, prepubertal children with ISS, randomized to receive daily rhGH 0.37 mg/kg/week (control, <i>n</i> = 16), LB03002 0.5 mg/kg/week (<i>n</i> = 14), or LB03002 0.7 mg/kg/week (<i>n</i> = 16). The primary endpoint was height velocity (HV) change at week 26. <b><i>Results:</i></b> At week 26, the least square (LS) means for HV change (cm/year) with control, LB03002 0.5 mg/kg/week, and LB03002 0.7 mg/kg/week were 5.08, 3.65, and 4.38, and the LS means for the change in height standard deviation score were 0.65, 0.49, and 0.58, respectively. The lower bound of the 90% confidence interval for the difference between LB03002 0.7 mg/kg/week and the control in the LS mean for HV change (–1.72) satisfied the noninferiority margin (–1.75). Adverse events were generally mild and short-lived. <b><i>Conclusion:</i></b> A once-weekly regimen of LB03002 0.7 mg/kg demonstrated noninferiority to the daily regimen of rhGH 0.37 mg/kg/week in terms of HV increments. LB03002 was well tolerated and its safety profile was comparable with that of daily rhGH.
DOI: 10.6084/m9.figshare.6619931.v1
title: Supplementary Material for: Once-Weekly Administration of Sustained-Release Growth Hormone in Korean Prepubertal Children with Idiopathic Short Stature: A Randomized, Controlled Phase II Study

description: <b><i>Background/Aims:</i></b> To determine the optimal dose of LB03002, a sustained-release, once-weekly formulation of recombinant human growth hormone (rhGH), and to compare its efficacy and safety with daily rhGH in children with idiopathic short stature (ISS). <b><i>Methods:</i></b> This multicenter, randomized, open-label, phase II study included<b><i></i></b> GH-naïve, prepubertal children with ISS, randomized to receive daily rhGH 0.37 mg/kg/week (control, <i>n</i> = 16), LB03002 0.5 mg/kg/week (<i>n</i> = 14), or LB03002 0.7 mg/kg/week (<i>n</i> = 16). The primary endpoint was height velocity (HV) change at week 26. <b><i>Results:</i></b> At week 26, the least square (LS) means for HV change (cm/year) with control, LB03002 0.5 mg/kg/week, and LB03002 0.7 mg/kg/week were 5.08, 3.65, and 4.38, and the LS means for the change in height standard deviation score were 0.65, 0.49, and 0.58, respectively. The lower bound of the 90% confidence interval for the difference between LB03002 0.7 mg/kg/week and the control in the LS mean for HV change (–1.72) satisfied the noninferiority margin (–1.75). Adverse events were generally mild and short-lived. <b><i>Conclusion:</i></b> A once-weekly regimen of LB03002 0.7 mg/kg demonstrated noninferiority to the daily regimen of rhGH 0.37 mg/kg/week in terms of HV increments. LB03002 was well tolerated and its safety profile was comparable with that of daily rhGH.
DOI: 10.6084/m9.figshare.6619649
title: Supplementary Material for: Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex

description: <b><i>Background:</i></b> Recent reports have suggested that the topical formulation of sirolimus is effective in treating facial angiofibromas in tuberous sclerosis complex (TSC). Here, we determined the safety and efficacy of 0.2% topical sirolimus for the treatment of facial angiofibroma and compared its effects based on age. <b><i>Method:</i></b> This was a retrospective study which involved 36 TSC patients with facial angiofibromas who were treated with 0.2% sirolimus ointment. Its effect was evaluated using the Facial Angiofibroma Severity Index (FASI). In order to observe its comparative effect based on patient age, a subgroup analysis was performed, between the adult group (&gt; 18 years old) and the pediatric group (≤18 years old). <b><i>Results:</i></b> The total FASI as well as its subcategories (erythema, size, and extent) showed statistically significant improvements after the topical treatment with 0.2% sirolimus ointment (FASI before treatment: 7.2 ± 1.1, FASI after treatment: 4.4± 1.4, <i>p</i> &lt; 0.001). Among the subcategories of FASI, the erythema was most significantly reduced with the fastest response to the treatment. In a subgroup analysis, the pediatric group showed significantly greater improvements in FASI (improvement of FASI in the pediatric group = 49.7 ± 12.2%, adult group = 27.9 ± 15.6%, <i>p</i> &lt; 0.001). The serial improvement analysis also showed that the pediatric group achieved a consistently greater improvement in FASI at all visits. Its 1-year application in 3 patients demonstrated a continuous maintenance effect. No significant adverse effects were observed. <b><i>Conclusion:</i></b> 0.2% sirolimus ointment is safe and effective for facial angiofibromas. Considering its higher efficacy in younger patients, an early initiation of the treatment is recommended.
DOI: 10.6084/m9.figshare.6619649.v1
title: Supplementary Material for: Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex

description: <b><i>Background:</i></b> Recent reports have suggested that the topical formulation of sirolimus is effective in treating facial angiofibromas in tuberous sclerosis complex (TSC). Here, we determined the safety and efficacy of 0.2% topical sirolimus for the treatment of facial angiofibroma and compared its effects based on age. <b><i>Method:</i></b> This was a retrospective study which involved 36 TSC patients with facial angiofibromas who were treated with 0.2% sirolimus ointment. Its effect was evaluated using the Facial Angiofibroma Severity Index (FASI). In order to observe its comparative effect based on patient age, a subgroup analysis was performed, between the adult group (&gt; 18 years old) and the pediatric group (≤18 years old). <b><i>Results:</i></b> The total FASI as well as its subcategories (erythema, size, and extent) showed statistically significant improvements after the topical treatment with 0.2% sirolimus ointment (FASI before treatment: 7.2 ± 1.1, FASI after treatment: 4.4± 1.4, <i>p</i> &lt; 0.001). Among the subcategories of FASI, the erythema was most significantly reduced with the fastest response to the treatment. In a subgroup analysis, the pediatric group showed significantly greater improvements in FASI (improvement of FASI in the pediatric group = 49.7 ± 12.2%, adult group = 27.9 ± 15.6%, <i>p</i> &lt; 0.001). The serial improvement analysis also showed that the pediatric group achieved a consistently greater improvement in FASI at all visits. Its 1-year application in 3 patients demonstrated a continuous maintenance effect. No significant adverse effects were observed. <b><i>Conclusion:</i></b> 0.2% sirolimus ointment is safe and effective for facial angiofibromas. Considering its higher efficacy in younger patients, an early initiation of the treatment is recommended.
DOI: 10.6084/m9.figshare.6619475
title: Supplementary Material for: Morphological Characterization of Basally Located Uninucleate Trophoblast Cells as Precursors of Bovine Binucleate Trophoblast Giant Cells

description: Binucleate trophoblast giant cells (TGCs) are one characteristic feature of the ruminant placenta. In cows, the frequency of TGCs remains constant for most of the duration of pregnancy. As TGCs are depleted by their fusion with uterine epithelial cells, they need to be constantly formed. It is still unclear whether they develop from stem cells within the trophectoderm or whether they can arise from any uninucleate trophoblast cell (UTC). Within the latter, generally accepted theory, a basally located uninucleate cell (BUC) without contact to the feto-maternal interface would represent a transient cell between a UTC and a TGC. So far, no evidence for the existence of such transient cells or for the presence of stem cells has been shown. The aim of the present study is to morphologically characterize the early stages of TGC development. Placentomal tissue of 6 pregnant cows from different gestational stages (gestational days 51–214) was examined for BUCs, UTCs, and TGCs either in serial sections (light and transmission electron microscopy, TEM, <i>n</i> = 3), in single sections (TEM, <i>n</i> = 2), or by serial block face-scanning electron microscopy (<i>n</i> = 1). These investigations revealed the occurrence of BUCs, as well as young TGCs showing contact with the basement membrane (BM), but without apical contact to the feto-maternal interface. The study morphologically defines these 2 cell types as early stages of TGC development and shows that binucleation of TGCs can precede detachment from the BM.
DOI: 10.6084/m9.figshare.6619475.v1
title: Supplementary Material for: Morphological Characterization of Basally Located Uninucleate Trophoblast Cells as Precursors of Bovine Binucleate Trophoblast Giant Cells

description: Binucleate trophoblast giant cells (TGCs) are one characteristic feature of the ruminant placenta. In cows, the frequency of TGCs remains constant for most of the duration of pregnancy. As TGCs are depleted by their fusion with uterine epithelial cells, they need to be constantly formed. It is still unclear whether they develop from stem cells within the trophectoderm or whether they can arise from any uninucleate trophoblast cell (UTC). Within the latter, generally accepted theory, a basally located uninucleate cell (BUC) without contact to the feto-maternal interface would represent a transient cell between a UTC and a TGC. So far, no evidence for the existence of such transient cells or for the presence of stem cells has been shown. The aim of the present study is to morphologically characterize the early stages of TGC development. Placentomal tissue of 6 pregnant cows from different gestational stages (gestational days 51–214) was examined for BUCs, UTCs, and TGCs either in serial sections (light and transmission electron microscopy, TEM, <i>n</i> = 3), in single sections (TEM, <i>n</i> = 2), or by serial block face-scanning electron microscopy (<i>n</i> = 1). These investigations revealed the occurrence of BUCs, as well as young TGCs showing contact with the basement membrane (BM), but without apical contact to the feto-maternal interface. The study morphologically defines these 2 cell types as early stages of TGC development and shows that binucleation of TGCs can precede detachment from the BM.
DOI: 10.6084/m9.figshare.6619448
title: Table 1: Metamorphic processes preserved in early Archean supracrustal rocks of the Barberton Greenstone Belt, South Africa

description: Whole rock oxygen stable isotope data for metabasalts of the Hooggenoeg Formation.
DOI: 10.6084/m9.figshare.6619448.v1
title: Table 1: Metamorphic processes preserved in early Archean supracrustal rocks of the Barberton Greenstone Belt, South Africa

description: Whole rock oxygen stable isotope data for metabasalts of the Hooggenoeg Formation.
DOI: 10.6084/m9.figshare.6619442
title: Table 3: Metamorphic processes preserved in early Archean supracrustal rocks of the Barberton Greenstone Belt, South Africa

description: White mica mineral compositions in sample H1-P7 in the uppermost Hooggenoeg Formation beneath the Kromberg Formation shear zone.
DOI: 10.6084/m9.figshare.6619442.v1
title: Table 3: Metamorphic processes preserved in early Archean supracrustal rocks of the Barberton Greenstone Belt, South Africa

description: White mica mineral compositions in sample H1-P7 in the uppermost Hooggenoeg Formation beneath the Kromberg Formation shear zone.
DOI: 10.6084/m9.figshare.6619439
title: Table 2: Metamorphic processes preserved in early Archean supracrustal rocks of the Barberton Greenstone Belt, South Africa

description: Kromberg metamorphic grade recalculated using chlorite compositions from Grosch <i>et al</i>. (2012) and the recently published chlorite geothermometry method of Bourdelle <i>et al</i>. (2013) that does not require estimates of XFe<sup>3+</sup>.
DOI: 10.6084/m9.figshare.6619439.v1
title: Table 2: Metamorphic processes preserved in early Archean supracrustal rocks of the Barberton Greenstone Belt, South Africa

description: Kromberg metamorphic grade recalculated using chlorite compositions from Grosch <i>et al</i>. (2012) and the recently published chlorite geothermometry method of Bourdelle <i>et al</i>. (2013) that does not require estimates of XFe<sup>3+</sup>.
DOI: 10.6084/m9.figshare.6619298
title: Economic decisions - good

description: economic, decisions, management
DOI: 10.6084/m9.figshare.6619298.v1
title: Economic decisions - good

description: economic, decisions, management
DOI: 10.6084/m9.figshare.6619280
title: conoidea_phylogeny_60.phylip

description: Concatenated alignment of all loci present in at least 60 samples in phylip format
DOI: 10.6084/m9.figshare.6619280.v1
title: conoidea_phylogeny_60.phylip

description: Concatenated alignment of all loci present in at least 60 samples in phylip format
DOI: 10.6084/m9.figshare.12891098
title: T_TEST_PRIMARY_DATASET

description: t-test result on a primary dataset of review comments without considering the quality of the comments
DOI: 10.6084/m9.figshare.12891098.v1
title: T_TEST_PRIMARY_DATASET

description: t-test result on a primary dataset of review comments without considering the quality of the comments
DOI: 10.6084/m9.figshare.12891095
title: T_TEST_REFIEND_DATASET

description: t-test result on a refined dataset of review comments with considering the quality of the comments
DOI: 10.6084/m9.figshare.12891095.v1
title: T_TEST_REFIEND_DATASET

description: t-test result on a refined dataset of review comments with considering the quality of the comments
DOI: 10.25904/1912/4
title: Univariate models of respiratory symptoms and environmental variables

description: This dataset represents spring and autumn results of Univariate General Linear Regression (GLM) significant predictors with alpha was set at .05. Positive and negative results are shown. Environmental measures on the same day, and up to 5 days of lag, predicted group mean respiratory symptom responses of 14 participants in S.E.Qld. Dependent measures were: SPEF, asthma score, wheeze, cough, difficulty breathing (dyspnea), reliever usage, preventer usage, itchy eyes, itchy nose, runny nose (rhinorrhea), sneezing, and blocked nose (congested nose). Air spora, compounds from air samples, pollutants and meteorological variables served as independent variables. They were: day length, mean atmospheric pressure, mean temperature, precipitation, mean windspeed, relative humidity at 9am, particulates &lt; 10 microns (PM10), heard thunder, ozone (O3), nitrogen monoxide (NO), nitrogen dioxide (NO2), Myrtaceae pollen, Poaceae pollen, Pinus pollen, Asteraceae pollen, Casuarina pollen, Acacia pollen, "other" pollen, Cladosporium, Alternaria, "other" fungi, benzoic acid, benzaldehyde, alpha pinene, beta pinene, 1,8 cineole, camphor, limonene, linalyl acetate and linalool.
DOI: 10.5281/zenodo.4003013
title: [Dataset] A Recharge Oscillator Model for Interannual Variability in Venus' Clouds

description: This dataset contains codes and data to reproduce figures 1-5 of the paper titled "A Recharge Oscillator Model for Interannual Variability in Venus' Clouds", currently under review at JGR Planets. The readme file included in the dataset gives a description of each file and their author.
DOI: 10.5281/zenodo.4003012
title: [Dataset] A Recharge Oscillator Model for Interannual Variability in Venus' Clouds

description: This dataset contains codes and data to reproduce figures 1-5 of the paper titled "A Recharge Oscillator Model for Interannual Variability in Venus' Clouds", currently under review at JGR Planets. The readme file included in the dataset gives a description of each file and their author.
DOI: 10.6084/m9.figshare.12891107.v1
title: Illumina whole genome resequencing of highland/lowland maize landraces and Zea mays ssp. parviglumis

description: This project resequenced 31 maize landraces from 6 populations to high depth (four highland populations: Mexican Highland, Southwest US highland, Guatemalan Highland, and the Andes; two lowland populations: Mexican Lowland and South American lowland) to study both maize demography during its diffusion from its origin center after domestication and the genomic architecture of highland adaptation. Four parviglumis individuals were also included to clarify evolution since domestication.
DOI: 10.6084/m9.figshare.12891107
title: Illumina whole genome resequencing of highland/lowland maize landraces and Zea mays ssp. parviglumis

description: This project resequenced 31 maize landraces from 6 populations to high depth (four highland populations: Mexican Highland, Southwest US highland, Guatemalan Highland, and the Andes; two lowland populations: Mexican Lowland and South American lowland) to study both maize demography during its diffusion from its origin center after domestication and the genomic architecture of highland adaptation. Four parviglumis individuals were also included to clarify evolution since domestication.